The prognostic role of the malignancy risk index in the diagnosis of ovarian neoplasms
DOI:
https://doi.org/10.37800/RM.1.2023.79-89Keywords:
ovarian tumors, morphology, malignancy risk index, cancerAbstract
Relevance: Ovarian neoplasms are a heterogeneous group in their histogenesis and morphological structure. Ovarian tumors of a benign nature have a favorable prognosis, although they are a precursor to malignant tumors. Different categories of tumors are rarely available for detection due to the inability to detect ovarian tumors at an early stage or causing deaths from ovarian cancer. Under these conditions, the role of the malignancy risk index becomes invaluable. In this study, we sought to evaluate the accuracy of the risk of malignancy index (RMI) when distinguishing histological types of ovarian neoplasms from ovarian tumors in our facility.
The study aimed to evaluate the role of RMI in the preoperative differentiation of benign and malignant tumors in women with ovarian cancer.
Materials and methods. The prospective study included 264 women ≥ 18 years old scheduled for surgery with ovarian tumors in three study groups (reproductive group, pre-menopause, postmenopause); ultrasound was performed, and the status of menopause and CA125 level were determined and RMI calculated. Postoperatively, all appendage formations were analyzed histologically, and RMI sensitivity, specificity, and prognostic value were calculated.
Results: Of the 264 patients, benign and malignant tumors were found in 90.9% and 9.1% of the participants in the reproductive group and 64.8% and 35.2% of the participants in the premenopausal and postmenopausal groups.
Conclusion: This study showed the accuracy of RMI in differentiating benign and malignant appendage formations.
References
Zhang R., Siu M.K.Y., Ngan H.Y.S., Chan K.K.L. Molecular biomarkers for the early detection of ovarian cancer // Int. J. Mol. Sci. – 2022. – Vol. 23(19). – Art. ID: 12041. https://doi.org/10.3390/ijms231912041.
Batool A., Rathore Z., Jahangir F., Javeed S., Nasir S., Chugtai A.S. Histopathological Spectrum of Ovarian Neoplasms: A Single-Center Study // Cureus. – 2022. – Vol. 7(14). – Art. ID: e27486. https://doi.org/10.7759/cureus.27486.
Chen J., Wei Z., Fu K., Duan Y., Zhang M., Li K., Guo T., Yin R. Non-apoptotic cell death in ovarian cancer: Treatment, resistance and prognosis // Biomed. Pharmacother. – 2022. – Vol. 150. – Art. ID: 112929. https://doi.org/10.1016/j.biopha.2022.112929.
Sasamoto N., Babic A., Rosner B.A., Fortner R.T., Vitonis A.F., Yamamoto H., Fichorova R.N., Titus L.J., Tjonneland A., Hansen L., Kvaskoff M., Fournier A., Mancini F.R., Boeing H., Trichopoulou A., Peppa E., Karakatsani A., Palli D., Grioni S., Mattiello A., Tumino R., Fiano V., Onland-Moret N.C., Weiderpass E., Gram I.T., Quirós J.R., Lujan-Barroso L., Sánchez M.J., Colorado-Yohar S., Barricarte A., Amiano P., Idahl A., Lundin E., Sartor H., Khaw K.T., Key T.J., Muller D., Riboli E., Gunter M., Dossus L., Trabert B., Wentzensen N., Kaaks R., Cramer D.W., Tworoger S.S., Terry K.L. Development and validation of circulating CA125 prediction models in postmenopausal women // J. Ovarian Res. – 2019. – Vol. 1(12). – Art. ID: 116. https://doi.org/10.1186/s13048-019-0591-4.
Jacobs I., Oram D., Fairbanks J., Turner J., Frost C., Grudzinskas J.G. A risk of malignancy index incorporating CA-125, ultrasound and menopau¬sal status for the accurate preoperative diagnosis of ovarian cancer // Br. J. Obstet. Gynaecol. – 1990. – Vol. 97. – P. 922-929. https://doi.org/10.1111/j.1471-0528.1990.tb02448.x
Ellwanger B., Schüler-Toprak S., Jochem C., Leitzmann M.F., Baurecht H. Anthropometric factors and the risk of ovarian cancer: A systematic review and meta-analysis // Cancer Rep. – 2022. – Vol. 11(5). – Art. ID: e1618. https://doi.org/10.1002/cnr2.1618.
Alorwan A., Bukhari M., Quayidkhalanazi O. Obesity as a risk and predictive factor for ovarian cancer among Saudi women: Hypothetical cloned artistic projection // Med. Sci. – 2022. – Vol. 26(120). https://doi.org/10.54905/disssi/v26i120/ms60e2016.
Sköld C., Koliadi A., Enblad G., Stalberg K., Glimelius I. Parity is associated with betterprognosis in ovarian germ cell tumors, but not in other ovariancancer subtypes // Int. J. Cancer. – 2022. – Vol. 150(5). – Р. 773-781. https://doi.org/10.1002/ijc.33844.
Toufakis V., Katuwal S., Pukkala E., Tapanainen J.S. Impact of parity on the incidence of ovarian cancer subtypes: a population-based case-control study // Acta Oncol. – 2021. – Vol. 7(60). – P. 850-855. https://doi.org/10.1080/0284186X.2021.1919754.
Gaitskell K., Green J., Pirie K., Barnes I., Hermon C., Reeves G.K., Beral V. Million Women Study Collaborators. Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective Million Women Study // Int. J. Cancer. – 2018.– Vol. 142(2). – P. 281-289. https://doi.org/10.1002/ijc.31063.
Qiu L., Yang F., Luo H. A preliminary study: The sequential use of the risk malignancy index and contrast-enhanced ultrasonography in differential diagnosis of adnexal masses // Medicine. – 2018. – Vol. 97(29). – Art. ID: e11536. https://doi.org/10.1097/MD.0000000000011536.
Shaik M., Divya S., Kadukuntla S., Annapoorna Y. Clinico-histopathological spectrum of ovarian tumors in tertiary care center rajahmundry // Indian J. Obstet. Gynecol. Res. – 2022. – Vol. 9(1). – P. 77-82. https://doi.org/10.18231/j.ijogr.2022.015.
Chakrabarti P.R., Chattopadhyay M., Gon S., Banik T. Role of histopathology in diagnosis of ovarian neoplasms: Our experience in a Tertiary Care Hospital of Kolkata, West Bengal, India // Niger Postgrad. Med. J. – 2021. – Vol. 28(2). – P. 108-111. https://doi.org/10.4103/npmj.npmj_491_21.
Dutta A., Imran R., Saikia P., Borgohain M. Histopathological spectrum pf ovarian neoplasms in a tertiary care hospital // Int. J. Contemp. Med. Res. – 2018. – Vol. 8(5). – Р. 1-4. https://www.ijcmr.com/uploads/7/7/4/6/77464738/ijcmr_2108_v1.pdf.
Dhende P.D., Patil L.Y., Jashnani K. Spectrum of ovarian tumors in a tertiary care hospital // Indian J. Pathol. Oncol. – 2021. – Vol. 1(8). – P. 133-139. https://www.ijpo.co.in/html-article/13283
Bobde V., Kawthalkar S., Kumbhalkar D., Clinicopathological spectrum of ovarian neoplasms in pre- and post-menopausal Indian women // IP Arch. Cytol. Histopathol. Res. – 2022. – Vol. 3(7). – Р. 157-163. https://doi.org/10.18231/j.achr.2022.035.
Saluja N., Makrande J.S., Hiwale K., Vagha S. Mature teratoma of bilateral ovary: A case report. // Med. Sci. – 2022. – Vol. 26. – P. 1-5. https://doi.org/10.54905/disssi/v26i124/ms239e2266.
Gardas V., Cherukuri P., Salomi S. Clinicopathological study of ovarian neoplasms – an institutional prespective // Asian J. Pharm. Clin. Res. – 2022. – Vol. 1 (15). – Р. 72-76. http://dx.doi.org/10.22159/ajpcr.2022v15i1.43429.
Balaji T.G., Nandish V.S., Shashikala P. Histomorphological study of ovarian neoplasms // Int. J. Clin. Diagn. Pathol. – 2020. – Vol. 1 (3). – P. 447-450. https://doi.org/10.33545/pathol.2020.v3.i1g.209.
Bandla S., Charan B. Hari V., Vissa S., Sai P.V., Rao N.M., Rao B.S.S., Grandhi E.B. Histopathological Spectrum of Ovarian Tumors in a Tertiary Care Hospital // Saudi J. Pathol Microbiol. – 2020. – Vol. 2(5). – P. 50-55. https://doi.org/10.36348/sjpm.2020.v05i02.002.
Narang S., Singh A., Nema S., Karode R. Spectrum of ovarian tumours – a five-year study // J. Pathol. Nepal. – 2017. – Vol. 7. – P. 1180-1183. https://doi.org/10.3126/jpn.v7i2.18002
Young R.H. Ovarian sex cord-stromal tumours and their mimics // Pathology. – 2018. – Vol. 1(50). – Р. 5-15. https://doi.org/10.1016/j.pathol.2017.09.007.
Bullock B., Larkin L., Turker L., Stampler K. Management of the Adnexal Mass: Considerations for the Family Medicine Physician // Front. Med. – 2022. – Vol. 9. – Art. ID: 913549. https://doi.org/10.3389/fmed.2022.913549.
Hafeez S., Sufian S., Beg M., Hadi Q., Jamil Y., Masroor I. Role of ultrasound in characterization of ovarian masses // Asian Pac. J. Cancer Prev. – 2013. – Vol. 1(14). – Р. 603-606. https://doi.org/10.7314/apjcp.2013.14.1.603.
Mukama T., Fortner R.T., Katzke V., Hynes L.C., Petrera A., Hauck S.M., Johnson T., Schulze M., Schiborn C., Rostgaard-Hansen A.L., Tjonneland A., Overvad K., Pérez M.J.S., Crous-Bou M., Chirlaque M.D., Amiano P., Ardanaz E., Watts E.L., Travis R.C., Sacerdote C., Grioni S., Masala G., Signoriello S., Tumino R., Gram I.T., Sandanger T.M., Sartor H., Lundin E., Idahl A., Heath A.K., Dossus L., Weiderpass E., Kaaks R. Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer // Br. J. Cancer. – 2022 – Vol. 9 (126). – P. 1301-1309. https://doi.org/10.1038/s41416-021-01697-z.
Hu X., Zhang J., Cao Y. Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study // BMC Cancer. – 2022. – Vol. 1(22). – Art. ID: 544. https://doi.org/10.1186/s12885-022-09637-7.
Gu Z., He Y., Zhang Y., Chen M., Song K., Huang Y., Li Q., Di W. Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer // J. Transl. Med. – 2018. – Vol. 1(16). – Art. ID: 114. https://doi.org/10.1186/s12967-018-1489-4.
Björkman K., Mustonen H., Kaprio T., Kekki H., Pettersson K., Haglund C., Böckelman C. CA125: A superior prognostic biomarker for colorectal cancer compared to CEA, CA19-9 or CA242 // Tumour Biol. – 2021. – Vol. 1 (43). – P. 57-70. https://doi.org/10.3233/TUB-200069.
Qing X., Liu L., Mao X. A clinical diagnostic value analysis of serum CA125, CA199, and HE4 in women with early ovarian cancer: Systematic review and meta-analysis // Comp. Math. Methods Med. – 2022. – Vol. 2022. – Art. ID: 9339325. https://doi.org/10.1155/2022/9339325.
Funston G., Mounce L.T.A., Price S., Rous B., Crosbie E.J., Hamilton W., Walter F.M. CA125 test result, test-to-diagnosis interval, and stage in ovarian cancer at diagnosis: A retrospective cohort study using electronic health records // Br. J. Gen. Pract. – 2021. – Vol. 71. – Р. 465-472. https://doi.org/10.3399/BJGP.2020.0859.
Mustafin C., Vesnin S., Turnbull A., Dixon M., Goltsov A., Goryanin I. Diagnostics of Ovarian Tumors in Postmenopausal Patients // Diagnostics. – 2022. – Vol. 12. – Art. ID: 2619. https://doi.org/10.3390/diagnostics12112619.
Aziz A.B., Najmi N. Is Risk Malignancy Indexing a Useful Tool for Predicting Malignant Ovarian Masses in Developing Countries? // Obstet. Gynecol. Int. – 2015. – Vol. 10330. – Art. ID: 951256. https://doi.org/10.1155/2015/951256.
Priyanka A.M., Jajoo S.S. Risk of malignancy index in preoperative evaluation of adnexal masses // J. Evol. Med. Dent. Sci. – 2018. – Vol. 7(50). – P. 5352-5357. https://doi.org/10.14260/jemds/2018/1185.
Zhang S., Yu S., Hou W., Li X., Ning C., Wu Y., Zhang F., Jiao Y.F., Lee L.T.O., Sun L. Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors // J. Ovar. Res. – 2019. – Vol. 12. – Art. ID: 87. https://doi.org/10.1186/s13048-019-0568-3.
Downloads
Published
How to Cite
Issue
Section
License
The articles published in this Journal are licensed under the CC BY-NC-ND 4.0 (Creative Commons Attribution – Non-Commercial – No Derivatives 4.0 International) license, which provides for their non-commercial use only. Under this license, users have the right to copy and distribute the material in copyright but are not permitted to modify or use it for commercial purposes. Full details on the licensing are available at https://creativecommons.org/licenses/by-nc-nd/4.0/.
